May 12 2010
The medical technology firm CardioMEMS is commercializing its proprietary wireless communication and sensing technology developed for the human body. The firm has completed a $37.9 million financing that provides the capital necessary to complete the CHAMPION clinical trial, started by the firm in 2007.
Currently this trial is evaluating the effectiveness and safety of the heart failure (HF) measurement system of CardioMEMS in 550 American patients. In 2009 the enrollment of patients was completed. The company expects the trial results to be delivered during the summer of 2010.
CardioMEMS EndoSure Sensor
This innovative miniature wireless HF sensor from CardioMEMS is implanted in the pulmonary artery of the patient through a catheter-based simple procedure. The pressure in this artery is then measured and displayed through a proprietary electronic monitoring system of CardioMEMS. Patients will also be able to measure their pulmonary artery pressure at home, once they are familiar with the process. The pressure data measured at home is then transmitted immediately to a secure database so that the implanting physician’s can review the data through the company’s website.
The Director of the Heart Failure Institute Philip Adamson of the Oklahoma Heart Institute and William Abraham, the Director of the Cardiovascular Medicine Division of the Ohio State University Medical Center are the trial’s co-principal investigators.
The CardioMEMS’ CEO and Founder Jay Yadav who is also an interventional cardiologist, informed that his company is happy with the continual support offered by Arcapita Ventures and its other investors. He added that the trial is likely to be completed during the coming months and that the FDA approval process for its heart failure pressure measurement solution will continue.